Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/jcm5020024 http://scihub22266oqcxt.onion/10.3390/jcm5020024 C4773780!4773780!26861406     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Med 2016 ; 5 (2): ä Nephropedia Template TP {{tp|p=26861406|t=2016. Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes |pdf=|usr=}}{{26861406}} gab.com Text Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes JO: J Clin Med http://www.kidney.de/pget.php?&tw=1&pmid=26861406 #FOAvip Tumor hypoxia is a pathophysiologic outcome of disrupted microcirculation with inadequate supply of oxygen, leading to enhanced proliferation, epithelial-mesenchymal transition (EMT), metastasis, and chemo-resistance. Epigenetic changes induced by hypoxia are well documented, and they lead to tumor progression. Recent advances show that DNA demethylation mediated by the Ten-eleven translocation (TET) proteins induces major epigenetic changes and controls key steps of cancer development. TET enzymes serve as 5mC (5-methylcytosine)-specific dioxygenases and cause DNA demethylation. Hypoxia activates the expression of TET1, which also serves as a co-activator of HIF-1? transcriptional regulation to modulate HIF-1? downstream target genes and promote epithelial-mesenchymal transition. As HIF is a negative prognostic factor for tumor progression, hypoxia-activated prodrugs (HAPs) may provide a favorable therapeutic approach to lessen hypoxia-induced malignancy. Twit Text FOAVip Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes ????J Clin Med http://www.kidney.de/pget.php?&tw=1&pmid=26861406 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26861406 #FOAvip English Wikipedia <ref>{{Cite pmid|26861406}}</ref> Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes #MMPMID26861406 Kao SH; Wu KJ; Lee WH J Clin Med 2016[Feb]; 5 (2): ä PMID26861406show ga Tumor hypoxia is a pathophysiologic outcome of disrupted microcirculation with inadequate supply of oxygen, leading to enhanced proliferation, epithelial-mesenchymal transition (EMT), metastasis, and chemo-resistance. Epigenetic changes induced by hypoxia are well documented, and they lead to tumor progression. Recent advances show that DNA demethylation mediated by the Ten-eleven translocation (TET) proteins induces major epigenetic changes and controls key steps of cancer development. TET enzymes serve as 5mC (5-methylcytosine)-specific dioxygenases and cause DNA demethylation. Hypoxia activates the expression of TET1, which also serves as a co-activator of HIF-1? transcriptional regulation to modulate HIF-1? downstream target genes and promote epithelial-mesenchymal transition. As HIF is a negative prognostic factor for tumor progression, hypoxia-activated prodrugs (HAPs) may provide a favorable therapeutic approach to lessen hypoxia-induced malignancy. äHypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigeneti(epmc).pdf DeepDyve Pubget Overpricing